Literature DB >> 23233714

Improving endocrine therapy for breast cancer: it's not that simple.

E Claire Dees, Lisa A Carey.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23233714     DOI： 10.1200/JCO.2012.46.2655

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  13 in total

1.  Targeting Metabolic Adaptations in the Breast Cancer-Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy.

Authors:  Qianying Zuo; Ayca Nazli Mogol; Yu-Jeh Liu; Ashlie Santaliz Casiano; Christine Chien; Jenny Drnevich; Ozan Berk Imir; Eylem Kulkoyluoglu-Cotul; Nicole Hwajin Park; David J Shapiro; Ben Ho Park; Yvonne Ziegler; Benita S Katzenellenbogen; Evelyn Aranda; John D O'Neill; Akshara Singareeka Raghavendra; Debu Tripathy; Zeynep Madak Erdogan
Journal:  Mol Cancer Res       Date:  2022-06-03       Impact factor: 6.333

2.  Cooperative Dynamics of AR and ER Activity in Breast Cancer.

Authors:  Nicholas C D'Amato; Michael A Gordon; Beatrice Babbs; Nicole S Spoelstra; Kiel T Carson Butterfield; Kathleen C Torkko; Vernon T Phan; Valerie N Barton; Thomas J Rogers; Carol A Sartorius; Anthony Elias; Jason Gertz; Britta M Jacobsen; Jennifer K Richer
Journal:  Mol Cancer Res       Date:  2016-08-26       Impact factor: 5.852

3.  Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.

Authors:  Vakaramoko Diaby; Georges Adunlin; Simon B Zeichner; Kiran Avancha; Gilberto Lopes; Stefan Gluck; Alberto J Montero
Journal:  Breast Cancer Res Treat       Date:  2014-07-11       Impact factor: 4.872

4.  Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer.

Authors:  Michelle M Williams; Nicole S Spoelstra; Spencer Arnesen; Kathleen I O'Neill; Jessica L Christenson; Jordan Reese; Kathleen C Torkko; Andrew Goodspeed; Emmanuel Rosas; Toru Hanamura; Sharon B Sams; Zheqi Li; Steffi Oesterreich; Rebecca B Riggins; Britta M Jacobsen; Anthony Elias; Jason Gertz; Jennifer K Richer
Journal:  Cancer Res       Date:  2020-11-12       Impact factor: 13.312

5.  ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.

Authors:  Kinga Wrobel; Yiru Chen Zhao; Eylem Kulkoyluoglu; Karen Lee Ann Chen; Kadriye Hieronymi; Jamie Holloway; Sarah Li; Tania Ray; Partha Sarathi Ray; Yosef Landesman; Alexander Edward Lipka; Rebecca Lee Smith; Zeynep Madak-Erdogan
Journal:  Mol Endocrinol       Date:  2016-08-17

Review 6.  Bridging the gap between clinicians and systems biologists: from network biology to translational biomedical research.

Authors:  Natini Jinawath; Sacarin Bunbanjerdsuk; Maneerat Chayanupatkul; Nuttapong Ngamphaiboon; Nithi Asavapanumas; Jisnuson Svasti; Varodom Charoensawan
Journal:  J Transl Med       Date:  2016-11-22       Impact factor: 5.531

Review 7.  Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers.

Authors:  Cigdem Selli; J Michael Dixon; Andrew H Sims
Journal:  Breast Cancer Res       Date:  2016-12-01       Impact factor: 6.466

8.  Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.

Authors:  J Thaddeus Beck; Gabriel N Hortobagyi; Mario Campone; Fabienne Lebrun; Ines Deleu; Hope S Rugo; Barbara Pistilli; Norikazu Masuda; Lowell Hart; Bohuslav Melichar; Shaker Dakhil; Matthias Geberth; Martina Nunzi; Daniel Y C Heng; Thomas Brechenmacher; Mona El-Hashimy; Shyanne Douma; Francois Ringeisen; Martine Piccart
Journal:  Breast Cancer Res Treat       Date:  2013-12-21       Impact factor: 4.872

9.  Molecular breast cancer subtypes prevalence in an indigenous Sub Saharan African population.

Authors:  Moses Galukande; Henry Wabinga; Florence Mirembe; Charles Karamagi; Alexzander Asea
Journal:  Pan Afr Med J       Date:  2014-04-05

10.  COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR.

Authors:  Renquan Lu; Xiaobo Hu; Junmei Zhou; Jiajun Sun; Alan Z Zhu; Xiaofeng Xu; Hui Zheng; Xiang Gao; Xian Wang; Hongchuan Jin; Ping Zhu; Lin Guo
Journal:  Nat Commun       Date:  2016-07-04       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.